Follow The Filings

VKTX Viking Therapeutics Inc.

Health Care, filed as VIKING THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.4%
  • $2.3M
  • 1 exit

In 2026 Q2 Ron Baron sold out of Viking Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 0.44%

Who owns VKTX

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.44% Hold 59,516 $2.3M History
Ron Baron, Bamco Inc. (Baron Capital) exited 2026 Q2 Last 2026 Q1 0.01% Exit −0.01% 125,486 $4.1M History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by VKTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VKTX insider trades
  • $150K bought by 1 insider
  • $2.7M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Neil William Aubuchon Chief Commercial Officer
    Buy
    $150K 4,475 shares at $33.50 New stake
    Traded Mar 10 Filed Mar 10
    ↗
  2. Matthew W Foehr Director
    Sale
    $562K 16,000 shares at $35.11 11% of stake
    Traded Jan 2 Filed Jan 5
    ↗
  3. Charles A Rowland Jr. Director
    Sale
    $2.1M 60,000 shares at $35.57 67% of stake
    Traded Oct 27, 2025 Filed Oct 28, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 stock grants, 18 sales to cover taxes, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 1.01,2.03,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.00 $0.00 $0.00
Net income -$85.9M -$109.96M -$359.64M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $367.22M $907.22M $715.6M
Total non-current assets * $1.26M $1.1M $0.131M
Total assets $368.49M $908.32M $715.73M
Total current liabilities $19.14M $27.41M $76.67M
Total non-current liabilities $936,000 $630,000 $0.00
Total equity $348.42M $880.28M $639.06M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$73.38M -$87.79M -$278.68M
Cash from investing -$179.09M -$553.37M $341.39M
Cash from financing $271.38M $612.46M $76.44M
Net change in cash * $18.91M -$28.69M $139.14M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.